JPMorgan Chase & Co. Reiterates “Neutral” Rating for AstraZeneca (AZN)
AstraZeneca (LON:AZN)‘s stock had its “neutral” rating reiterated by investment analysts at JPMorgan Chase & Co. in a note issued to investors on Tuesday, AR Network reports.
A number of other firms have also recently commented on AZN. Analysts at Leerink Swann raised their price target on shares of AstraZeneca (LON:AZN) from GBX 50 ($0.81) to GBX 51 ($0.82) in a research note to investors on Monday. They now have a “market perform” rating on the stock. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Monday. They now have a GBX 3,200 ($51.63) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Monday. They now have a GBX 3,425 ($55.26) price target on the stock. Eleven equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of GBX 3,103.01 ($50.06).
AstraZeneca (LON:AZN) traded down 0.12% on Tuesday, hitting GBX 3211.5002. The stock had a trading volume of 1,420,904 shares. AstraZeneca has a 1-year low of GBX 2786.00 and a 1-year high of GBX 3544.50. The stock’s 50-day moving average is GBX 3215.42 and its 200-day moving average is GBX 3252.57. The company’s market cap is £40.208 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.